Trial Profile

A randomized, open label study of the effect of Peginterferon alfa-2a (40KD) (PEGASYS) plus entecavir (Baraclude) combination therapy on quantitative changes in HBeAg in treatment-naive patients with HBeAg positive chronic hepatitis B.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 09 Jun 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Jun 2016 Planned no. of patients is given as 219 in NCT, however I have retained 218 as per the results published in the Clinical Infectious Diseases (3146603)
16 Apr 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
25 Mar 2010 Planned number of patients changed from 228 to 210 as reported by Roche record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com